Home YSOPIA Bioscience

YSOPIA Bioscience

In operation
-
Gut Microbiota-Oriented Drug Developer
Basic
Enterprise Profile

Basic Information

YSOPIA Bioscience Provides Gut Microbiota-Directed Therapeutics for Obesity and Related Cardiometabolic Disorders. The company’s drugs contain living organisms such as bacteria, treating obesity and metabolic disorders through their effects on the gut microbiota and intestinal mucosa, enabling healthcare companies to access innovative microbiome-based therapies.
YSOPIA Bioscience
Bordeaux,NewAquitaine,France
15~50 people
January 01, 2010
contact@ysopia.bio

Enterprise Profile

Industrial Sector
New Drug Development Immune Cell Therapy
Technology
Immunological Techniques Microbial/Viral Technology
Concept
Tumor Therapeutic Products Obesity Asthma Irritable Bowel Syndrome
Application Scenarios
Innovative Drugs